Heron Therapeutics, Inc. (HRTX)
NASDAQ: HRTX · Real-Time Price · USD
0.8173
-0.0227 (-2.70%)
At close: Mar 19, 2026, 4:00 PM EDT
0.8190
+0.0017 (0.21%)
After-hours: Mar 19, 2026, 6:25 PM EDT

Heron Therapeutics Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
154.9144.29127.04107.6786.35
Revenue Growth (YoY)
7.36%13.57%17.99%24.70%-2.59%
Cost of Revenue
41.3538.6565.1154.8746.02
Gross Profit
113.56105.6461.9452.840.33
Selling, General & Admin
103.67100.48133.42144.75127.33
Research & Development
12.4316.6839.1382.7130.82
Total Operating Expenses
116.1117.17172.55227.46258.15
Operating Income
-2.54-11.53-110.62-174.66-217.83
Interest Income
1.953.553.361.640.43
Interest Expense
-9.61-6.03-3.87-2.47-2.41
Other Non-Operating Income (Expense)
-100.430.56-6.53-0.88
Total Non-Operating Income (Expense)
-17.66-2.050.06-7.37-2.86
Pretax Income
-20.2-13.58-110.56-182.02-220.68
Net Income
-20.2-13.58-110.56-182.02-220.68
Net Income to Common
-20.2-13.58-110.56-182.02-220.68
Shares Outstanding (Basic)
16715213810998
Shares Outstanding (Diluted)
16715213810998
Shares Change (YoY)
9.35%10.36%26.87%10.57%8.48%
EPS (Basic)
-0.12-0.09-0.80-1.67-2.24
EPS (Diluted)
-0.12-0.09-0.80-1.67-2.24
Free Cash Flow
-27.91-24.24-60.33-148.74-206.38
Free Cash Flow Per Share
-0.17-0.16-0.44-1.37-2.10
Gross Margin
73.31%73.21%48.75%49.04%46.70%
Operating Margin
-1.64%-7.99%-87.07%-162.21%-252.27%
Profit Margin
-13.04%-9.41%-87.02%-169.05%-255.58%
FCF Margin
-18.02%-16.80%-47.49%-138.14%-239.01%
EBITDA
-0.22-9.04-107.72-171.77-214.81
EBITDA Margin
-0.14%-6.26%-84.79%-159.53%-248.77%
EBIT
-2.54-11.53-110.62-174.66-217.83
EBIT Margin
-1.64%-7.99%-87.07%-162.21%-252.27%
Updated Feb 26, 2026. Data Source: Fiscal.ai. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q